Verastem (VSTM)

[stockguard]

Just posting this as i`m keeping up on all aspects for myself and others to make informed decisions.....
AbbVie spikes the ball at ASH 2017
Company: AbbVie (ABBV) and Roche (OTCQX:RHHBY)

Therapy: Venetoclax and rituximab

Disease: Chronic lymphocytic leukemia (CLL)

News: ABBV and RHHBY presented the full data for the phase 3 MURANO study at ASH 2017. The results showed that venetoclax (branded Venclexta) combined with rituximab (branded Rituxan) yielded superior progression-free survival compared with the standard of care combination of bendamustine and rituximab in patients with relapsed/refractory CLL. A total of 84.9% in the venetoclax arm remained progression free at 2 years, compared with 36.3% in the control arm. The venetoclax arm also had substantially higher response rates compared with the control treatment. No new safety signals were noted, and patients seemed to tolerate venetoclax-rituximab slightly better than they did in the control arm.

Looking forward: These results are potentially game changing for venetoclax in CLL. Considering that there was already quite a lot of excitement underneath this drug, that's saying a lot. However, it is now clear that venetoclax-rituximab will supplant bendamustine-rituximab in the treatment algorithm for patients with previously treated CLL. With this, ABBV continues its march toward the first-line setting, and they have yet to be repelled. So this is very exciting, and I fully expect to see a supplemental filing in the near future.

https://seekingalpha.com/article/4131503-3-things-biotech-learn-today-december-13-2017